Clinical trials: Obsessive-Compulsive Disorder
- Condition Obsessive-Compulsive Disorder
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Obsessive-Compulsive Disorder
A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder
The purpose of this study was to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in participants with Obsessive Compulsive Disorder (OCD).
- Trial name
- NCT04693351
- Testing
- Troriluzole
- Where
- 89 sites in United States, Canada and 5 more
- Volunteers
- 589 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder
The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive disorder (OCD) who had an inadequate response to selective serotonin reuptake…
- Trial name
- NCT03299166
- Testing
- Troriluzole
- Where
- 57 sites in United States
- Volunteers
- 426 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Anxiety, Obsessive-Compulsive Disorder
Virtual Reality System for Anxiety and OCD
Cognitive Behavioral Therapy with fear provoking exposures is the most effective therapy for anxiety disorders. The investigators aim to enhance this therapy with the use of virtual reality exposures.
- Trial name
- NCT03636022
- Testing
- VR System, Control
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Minnesota HealthSolutions
Obsessive Compulsive Disorder
Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)
To evaluate the long-term impact of treatment with sertraline on aspects of cognitive, emotional and physical development and pubertal maturation in pediatric subjects ages 6 to 16 years (inclusive) with a diagnosis of anxiety…
- Trial name
- SPRITES (NCT01302080)
- Testing
- sertraline, psychotherapy
- Where
- 44 sites in United States
- Volunteers
- 941 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Obsessive Compulsive Disorder
A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder
The objective of the first phase of this study is to evaluate the efficacy of fluvoxamine compared to placebo on change in total score of Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) 10-item…
- Trial name
- NCT01933919
- Testing
- Fluvoxamine maleate
- Volunteers
- 38 people
- Sponsor
- AbbVie
Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses
Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy
The purpose of this study is to determine whether AFQ056 as an add on therapy to SSRIs can have beneficial effects by reducing the total score of Y-BOCS (Yale and Brown Obsessive Compulsive Scale) in OCD patients resistant to…
- Trial name
- NCT01813019
- Testing
- AFQ056
- Where
- 15 sites in United States, Bulgaria and 3 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals